
A new anticoagulant with a novel mechanism of action has received its first approval in the United States. While it is significant for expanding preventive options by demonstrating an effect that lowers the risk of stroke recurrence when added to existing antiplatelet therapy, it cannot replace existing anticoagulants used for conditions such as atrial fibrillation.
According to the pharmaceutical industry on the 16th, the U.S. Food and Drug Administration (FDA) approved Bayer’s “Sahavo” (generic name: asundexian) 50 mg on the 9th (local time). This is the first approval in the U.S. for a drug that inhibits blood coagulation factor XIa (FXIa). It is intended to be taken once daily, in addition to antiplatelet therapy, by adults who have recently experienced non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).
Ischemic stroke occurs when a blood vessel in the brain becomes blocked. Among these, non-cardioembolic cases are distinguished from those caused by clots originating in the heart. In Korea, antiplatelet agents such as aspirin and clopidogrel are used to prevent recurrence of non-cardioembolic stroke. For some patients with mild acute cerebral infarction or high-risk transient ischemic attack, the two drugs are used in combination for an initial period.
Sahavo differs from existing antiplatelet agents in the pathway by which it inhibits clot formation. While aspirin and clopidogrel inhibit platelet activation and aggregation, Sahavo inhibits blood coagulation factor XIa, blocking the process that amplifies thrombin production. Thrombin is an enzyme involved in clotting blood and forming clots. By adding Sahavo to existing antiplatelet agents, it targets two different pathways: platelets and coagulation factors.
The basis for approval was the Phase 3 clinical trial “OCEANIC-STROKE,” which involved 12,327 patients. Researchers administered Sahavo or a placebo in addition to existing antiplatelet therapy to patients within 72 hours of experiencing non-cardioembolic ischemic stroke or high-risk transient ischemic attack. The incidence rate of ischemic stroke was 6.2% in the Sahavo group and 8.4% in the placebo group. The relative risk was 26% lower, with an absolute difference in incidence rates of 2.2 percentage points.
This means that it further reduced the residual risk of stroke recurrence even while patients were receiving antiplatelet therapy. However, this is not a result showing that Sahavo monotherapy is superior to aspirin or clopidogrel. The efficacy was verified from the clinical trial stage by adding the drug to antiplatelet therapy, and the U.S. approval was also granted on the premise of combination use.
Overseas researchers have previously noted that combined antithrombotic therapy for long-term stroke recurrence prevention had not yielded results due to insufficient efficacy or increased bleeding. In this study, adding Sahavo reduced the occurrence of ischemic stroke without statistically significantly increasing the overall rate of major bleeding. However, an accompanying editorial in the journal assessed that additional research is needed to confirm whether the net benefit of the treatment is maintained over the long term.
Bleeding risk still needs to be considered. In the clinical trial, the overall incidence rate of major bleeding was similar at 1.9% in the Sahavo group and 1.7% in the placebo group, but the FDA stated that there were more major bleeding events in the Sahavo group among patients over 75 years old and during the first 90 days of treatment. Gastrointestinal bleeding also occurred more frequently in the Sahavo group.
This approval does not demonstrate the potential to replace existing anticoagulants. Sahavo was not approved for stroke prevention in patients with atrial fibrillation. In a separate clinical trial previously conducted comparing Sahavo with the existing anticoagulant apixaban in patients with atrial fibrillation, the trial was terminated early because Sahavo’s efficacy in preventing stroke and systemic embolism was inferior. This approval is based on results obtained from combination use with antiplatelet agents in a different patient population.
Bayer plans to begin shipping Sahavo in the U.S. in mid-to-late this month. According to Bayer’s announcement, it was approved in China on the 26th of last month, and approval reviews are underway in Europe and Japan. However, plans for domestic introduction have not yet been disclosed.
A Bayer Korea official said, “There is nothing finalized regarding domestic approval yet, but we will strive to complete domestic introduction as soon as possible.”